Moleculin to Present at the Oppenheimer 32nd Annual Healthcare Conference

Rhea-AI Summary

Moleculin Biotech, Inc. (Nasdaq: MBRX) announced that its Chairman and CEO, Walter Klemp, will present at the Oppenheimer 32^nd Annual Healthcare Conference on March 17, 2022, at 9:20 AM ET. The company focuses on developing drug candidates for resistant tumors and viruses, including its lead program, Annamycin, for treating acute myeloid leukemia and soft tissue sarcoma. The presentation will be available via a live webcast, and a replay will be archived for 90 days. Investors can expect virtual one-on-one meetings with management.

HOUSTON, March 11, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, Chairman and CEO of Moleculin Biotech, will present at the virtual Oppenheimer 32^nd Annual Healthcare Conference on Thursday, March 17, 2022 at 9:20 AM ET.

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

The live webcast of the presentation will be accessible on the Events page in the Investors section of the Company's website (www.moleculin.com). The webcast replay will be archived for 90 days following the event.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The Company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of COVID-19 and other viruses, as well as cancer indications including brain tumors, pancreatic and other cancers.

For more information about the Company, please visit www.moleculin.com and connect on Twitter, LinkedIn and Facebook.

Investor Contact:

JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculin-to-present-at-the-oppenheimer-32nd-annual-healthcare-conference-301500552.html

SOURCE Moleculin Biotech, Inc.

FAQ

When is Moleculin Biotech's presentation at the Oppenheimer Conference?

Moleculin Biotech will present at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, at 9:20 AM ET.

Who will represent Moleculin Biotech at the Oppenheimer Conference?

Walter Klemp, Chairman and CEO of Moleculin Biotech, will represent the company at the conference.

How can I access the Moleculin Biotech presentation?

The presentation can be accessed via a live webcast on the company's Investors page, with a replay available for 90 days.

What is the focus of Moleculin Biotech's drug candidates?

Moleculin Biotech focuses on drug candidates targeting highly resistant tumors and viruses, including acute myeloid leukemia and soft tissue sarcoma.

What is Annamycin developed by Moleculin Biotech?

Annamycin is a next-generation anthracycline designed to treat relapsed or refractory acute myeloid leukemia and soft tissue sarcoma while avoiding cardiotoxicity.